HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Severe cardiac involvement in children with systemic sclerosis and myositis.

AbstractOBJECTIVE:
To assess the outcome of children with systemic sclerosis (SSc) and features of polymyositis.
METHODS:
The charts of 4 children who met the American College of Rheumatology criteria for SSc and had features of polymyositis, as defined by the presence of proximal muscle weakness and elevated serum creatine phosphokinase or aldolase level, were retrospectively reviewed.
RESULTS:
All children had multivisceral involvement including (1) myocardial perfusion defects in all cases, with mild to severe dilated cardiomyopathy in 3; (2) lung restrictive syndrome in 3; (3) mild to severe esophageal involvement in all cases; and (4) severe intestinal dysfunction in one child. Combination therapy of corticosteroids, methotrexate (MTX), and cyclosporine resulted in improved skin thickness and muscle strength scores in all cases, as well as in lung restrictive syndrome in 2, but was not effective regarding the progression of intestinal malabsorption in one patient, esophageal dysmotility in 3 patients, and dilated cardiomyopathy in 3. Endstage cardiac failure caused 2 deaths. In one child, heart transplantation was performed for the first time in this indication.
CONCLUSION:
Children with diffuse cutaneous SSc and features of polymyositis are prone to develop severe cardiomyopathy. Combination therapy of corticosteroids, MTX, and cyclosporine seems to be active on muscle, skin, and lung involvement but does not impair progression of esophageal or myocardial dysfunction. Heart transplantation might be considered, as an experimental treatment, in young patients with severe cardiomyopathy and no other irreversible organ damage.
AuthorsPierre Quartier, Damien Bonnet, Jean-Christophe Fournet, Christine Bodemer, Philippe Acar, Marie Ouachée-Chardin, Jérome Le Bidois, Anne-Marie Prieur
JournalThe Journal of rheumatology (J Rheumatol) Vol. 29 Issue 8 Pg. 1767-73 (Aug 2002) ISSN: 0315-162X [Print] Canada
PMID12180742 (Publication Type: Journal Article)
Chemical References
  • Immunosuppressive Agents
  • Cyclosporine
  • Prednisone
  • Methotrexate
Topics
  • Adolescent
  • Cardiomyopathies (etiology, mortality, pathology)
  • Child
  • Cyclosporine (therapeutic use)
  • Drug Therapy, Combination
  • Humans
  • Immunosuppressive Agents (therapeutic use)
  • Male
  • Methotrexate (therapeutic use)
  • Polymyositis (complications, drug therapy, pathology)
  • Prednisone (therapeutic use)
  • Scleroderma, Systemic (complications, drug therapy, pathology)
  • Survival Rate
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: